🏛️ Verified NIH Record • Updated 2026-06-22
Checkpoint Inhibitor Associated Diabetes Mellitus: Early Recognition and Treatment (CERT) Project: A Pilot Study (NCT07257068)
🟡 Not Yet Recruiting Observational / Diagnostic 📋 Clinical Research Protocol Sponsor: M.D. Anderson Cancer Center
🩺 Plain-English Summary (8th-Grade Level)
To find out if taking a drug called infliximab (the "study drug") is safe and effective in reversing insulin dependence in CIADM.
Who can join: Review the eligibility criteria below.
Location: MD Anderson Cancer Center — Houston, Texas
Age range: 18 Years
🧪 Interventions in This Study
- Infliximab (OTHER)
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- MD Anderson Cancer Center — Houston, Texas
📞 Contact the Study Coordinator
Phone: (832) 291-6069
Email: piyer@mdanderson.org
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
Explore by condition: All Checkpoint Inhibitor clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.